ID: ALA5291086

Max Phase: Preclinical

Molecular Formula: C18H20F2N3O9P

Molecular Weight: 491.34

Representations

Canonical SMILES:  Nc1ccn([C@@H]2O[C@H](COP(=O)(O)OCC(=O)OCc3ccccc3)[C@@H](O)C2(F)F)c(=O)n1

Standard InChI:  InChI=1S/C18H20F2N3O9P/c19-18(20)15(25)12(32-16(18)23-7-6-13(21)22-17(23)26)9-30-33(27,28)31-10-14(24)29-8-11-4-2-1-3-5-11/h1-7,12,15-16,25H,8-10H2,(H,27,28)(H2,21,22,26)/t12-,15-,16-/m1/s1

Standard InChI Key:  SPEUSDCRTLOENI-DAXOMENPSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type:

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 491.34

Molecular Weight (Monoisotopic): 491.0905

AlogP: 0.60

#Rotatable Bonds: 9

Polar Surface Area: 172.43

Molecular Species: ACID

HBA: 11

HBD: 3

#RO5 Violations: 1

HBA (Lipinski): 12

HBD (Lipinski): 4

#RO5 Violations (Lipinski): 1

CX Acidic pKa: 1.82

CX Basic pKa:

CX LogP: 0.14

CX LogD: -2.24

Aromatic Rings: 2

Heavy Atoms: 33

QED Weighted: 0.33

Np Likeness Score: 0.66

References

1. Zhang L, Qi K, Xu J, Xing Y, Wang X, Tong L, He Z, Xu W, Li X, Jiang Y..  (2023)  Design, Synthesis, and Anti-Cancer Evaluation of Novel Cyclic Phosphate Prodrug of Gemcitabine.,  66  (6): [PMID:36867101] [10.1021/acs.jmedchem.3c00006]

Source

Source(1):

• Scientific Literature